Industry Lunchtime Session
Sponsored by Merz Therapeutics

Thursday, 15 January – 12:30 – 13:45

This symposium focuses on enhancing clinical decision-making through outcome-guided dosing strategies for Botulinum Toxin A (BoNT-A). It emphasizes recognizing patients who may be suboptimally dosed—particularly those with complex spasticity patterns—and introduces the GO-FAST tool as a structured framework for personalized goal setting and treatment planning. The session also reinforces the importance of dosing confidence, supported by the established long-term tolerability and low immunogenicity profile associated with certain BoNT-A formulations.

Key Takeaways for Participants:

• Identify patients with missed therapeutic opportunities due to suboptimal dosing and understand the impact on functional outcomes and quality of life.
• Gain practical experience using the GO-FAST tool to align treatment with individualized patient goals.
• Strengthen confidence in making personalized dosing decisions, supported by scientific evidence on long-term safety and immunogenicity.

Speakers are: Prof. Dr. Alessio Baricich, Italy; Dr. Bo Biering-Sorensen, Denmark; Dr. Stefano Carda, Switzerland; Prof. Dr. P. Albrecht, Germany